HPV/Chlamydia trachomatis co-infection: Metagenomic analysis of cervical microbiota in asymptomatic women

New Microbiologica

Volumn 41, Issue 1, 2018, Pages 34-41

  Di Pietro, Marisa ^a   Filardo, Simone ^a   Porpora, Maria Grazia ^b   Recine, Nadia ^b   Latino, Maria Agnese ^c   Sessa, Rosa ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Sant'Anna Hospital   (Italy)

Author keywords

Cervical microbiota; Chlamydia trachomatis; Coinfection; HPV; Metagenomic analysis.

Indexed keywords

BACTERIAL RNA; RNA 16S;

ADULT; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COMPLICATION; FEMALE; GENETICS; HUMAN; MICROBIOLOGY; MIXED INFECTION; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTION; PATHOLOGY; UTERINE CERVIX DISEASE; VIROLOGY;

ADULT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COINFECTION; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; UTERINE CERVICAL DISEASES;

EID: 85041120352     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Brotman R.M. (2011). Vaginal microbiome and sexually transmitted infections: An epidemiologic perspective, J. Clin. Invest. 121, 4610-4617.
2. Brotman R.M., Shardell M.D., Gajer P., Tracy J.K., Zenilman J.M., et al. (2014). Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J. Infect. Dis. 210, 1723-1733.
3. Caporaso J.G., Kuczynski J., Stombaugh J., Bittinger K., Bushman F.D., et al. (2010). QIIME allows analysis of high-Throughput community sequencing data. Nat. Methods. 7, 335-336.
4. Dareng E.O., Ma B., Famooto A.O., Akarolo-Anthony S.N., Offiong R.A., et al. (2016). Prevalent high-risk HPV infection and vaginal microbiota in Nigerian women. Epidemiol. Infect. 144, 123-137.
5. Davies B., Turner K.M., Leung S., Yu B.N., Frolund M., et al. (2017). Comparison of the population excess fraction of Chlamydia trachomatis infection on pelvic inflammatory disease at 12-months in the presence and absence of chlamydia testing and treatment: Systematic review and retrospective cohort analysis. PLoS One. 15, e0171551.
6. de Sanjosé S., Diaz M., Castellsagué X., et al. (2007). Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-Analysis. Lancet Infect Dis. 7, 453-459.
7. Downey A.S., Da Silva S.M., Olson N.D., Filliben J.J., Morrow J.B. (2012). Impact of processing method on recovery of bacteria from wipes used in biological surface sampling, Appl. Environ. Microbiol. 78, 5872-5881.
8. Edgar R.C. (2010). Search and clustering orders of magnitude faster than BLAST. Bioinformatics. 26, 2460-2461.
9. Edgar R.C., Haas B.J., Clemente J.C., Quince C., Knight R. (2011). UCHIME improves sensitivity and speed of chimera detection. Bioinformatics. 27, 2194-2200.
10. Filardo S., Di Pietro M., Porpora M.G., Recine N, Farcomeni A., Latino M.A., Sessa R. (2017). Diversity of cervical microbiota in asymptomatic Chlamydia trachomatis genital infection: A Pilot Study. Front. Cell. Infect. Microbiol. doi.org/10.3389/fcimb.2017.00321.
11. Frieden R.T., Jaffe W.H., Cono J., Richards L.C., Iademarco F.M. (2015). Centers for Disease Control and Prevention (CDC). Sexually Transmitted Diseases Treatment Guidelines. 2015, MMWR Recomm. Rep. 64, 1-137.
12. Gao W., Weng J., Gao Y., Chen X. (2013). Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: A cross-sectional study. BMC Infect. Dis. 13, 271.
13. Haggerty C.L., Gottlieb S.L., Taylor B.D., Low N., Xu F., et al. (2010). Risk of sequelae after Chlamydia trachomatis genital infection in women. J. Infect. Dis. 201, S134-155.
14. Lanjouw E., Ouburg S., de Vries H.J., Stary A., Radcliffe K., Unemo, M. (2016). 2015 European guideline on the management of Chlamydia trachomatis infections. Int. J. STD AIDS. 27, 333-348.
15. Lee J.E., Lee S., Lee H., Song Y.M., et al. (2013). Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS One. 8, e63514.
16. Lewis F.M., Bernstein K.T., Aral S.O. (2017). Vaginal microbiome and its relationship to behavior, sexual health, and sexually transmitted diseases. Obstet. Gynecol. 129, 643-654.
17. Ling Z. Kong J., Liu F., Zhu H., Chen X., et al. (2010). Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics. 11, 488.
18. Ling Z., Liu X., Chen X., Zhu H., Nelson K.E., et al. (2011). Diversity of cervicovaginal microbiota associated with female lower genital tract infections. Microb. Ecol. 61, 704-714.
19. Lozupone C., Knight, R. (2005). UniFrac: A new phylogenetic method for comparing microbial communities. Appl. Environ. Microbiol. 71, 8228-8235.
20. Lozupone C.A., Hamady M., Kelley S.T., Knight R. (2007). Quantitative and qualitative beta diversity measures lead to different insights into factors that structure microbial communities. Appl. Environ. Microbiol. 73, 1576-1585.
21. Ma B., Forney L.J., Ravel J. (2012). Vaginal microbiome: rethinking health and disease. Annu. Rev. Microbiol. 66, 371-389.
22. Ma B., Brotman R.M., Gajer P, Fadrosh D., Mahurkar A., et al. (2013). Association between Chlamydia trachomatis genital infection and the vaginal microbiome. Sex. Transm. Infect. 89, A1-A428.
23. Magoč T., Salzberg S.L. (2011). FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 27, 2957-2963.
24. Martin M. (2011). Cutadapt removes adapter sequences from high-Throughput sequencing reads. EMBnet. Journal 17, 10-12.
25. Mastromarino P., Di Pietro M., Schiavoni G., Nardis C., Gentile M., Sessa R. (2014). Effects of vaginal lactobacilli in Chlamydia trachomatis infection. Int J Med Microbiol. 304, 654-61.
26. Mitra A., MacIntyre D.A., Marchesi J.R., et al. (2016a). The vaginal microbiota, human papillomavirus infection and cervical intraepithelial neoplasia: what do we know and where are we going next? Microbiome. 4, 58.
27. Newman L., Rowley J., Vander Hoorn S., Wijesooriya N.S., Unemo M., et al. (2015). Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting. PLoS One. 10, e0143304.
28. Niyibizi J., Zanré N., Mayrand M.H., Trottier H. (2017). The association between adverse pregnancy outcomes and maternal human papillomavirus infection: A systematic review protocol. Syst Rev. 6, 53.
29. Oakeshott P., Aghaizu A., Reid F., Howell-Jones R., Hay P.E., et al. (2012). Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ. 344, e4168.
30. Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., et al. (2013). The SILVA ribosomal RNA gene database project: improved data processing and web-based tools, Nucleic Acids Res. 41, D590-D596.
31. Scott M., Stites D.P., Moscicki A.B. (1999). Th1 cytokine patterns in cervical human papillomavirus infection. Clin. Diagn. Lab. Immunol. 6, 751-755.
32. Segata N., Izard J., Waldron L., Gevers D., Miropolsky L., et al. (2011). Metagenomic biomarker discovery and explanation. Genome Biol. 12, R60.
33. Sessa R., Di Pietro M., De Santis F., Filardo S., Ragno R., et al. (2015). Effects of Mentha suaveolens essential oil on Chlamydia trachomatis. Biomed Res Int. 2015, 508071.
34. Sessa R., Di Pietro M., Filardo S., Bressan A., Rosa L., et al. (2017a). Effect of bovine lactoferrin on Chlamydia trachomatis infection and inflammation. Biochem Cell Biol. 95, 34-40.
35. Sessa R., Di Pietro M., Filardo S., Bressan A., Mastromarino P., et al. (2017b). Lactobacilli-Lactoferrin interplay in Chlamydia trachomatis infection. Pathog Dis. 75.
36. Shannon B., Yi T.J., Perusini S., Gajer P., Ma B., et al. (2017). Association of HPV infection and clearance with cervicovaginal immunology and the vaginal microbiota. Mucosal Immunol. Jan 25.
37. Shaw K., Coleman D., O'Sullivan M., Stephens N. (2011). Public health policies and management strategies for genital Chlamydia trachomatis infection. Risk Manag. Healthc Policy. 4, 57-65.
38. Silins I., Ryd W., Stre A., Wadell G., Tornberg S., et al. (2005). Chlamydia trachomatis infection and persistence of human papillomavirus. Int. J. Cancer. 116, 110-115.
39. Silva J., Cerqueira F., Medeiros R. (2014). Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch. Gynecol. Obstet. 289, 715-723.
40. van de Wijgert J.H., Borgdorff H., Verhelst R., Crucitti T., Francis S., et al. (2014). The vaginal microbiota: what have we learned after a decade of molecular characterization? PLoS One. 9, e105998.
41. van der Veer C., Bruisten S.M., van der Helm J.J., de Vries H.J., van Houdt, R. (2017). The Cervicovaginal Microbiota in Women Notified for Chlamydia trachomatis Infection: A Case-Control Study at the Sexually Transmitted Infection Outpatient Clinic in Amsterdam, The Netherlands. Clin. Infect. Dis. 64, 24-31.
42. Wiesenfeld H.C. (2017). Screening for Chlamydia trachomatis Infections in Women. N. Engl. J. Med. 376, 765-773.
43. You H., Liu Y., Agrawal N. Prasad C.K., Edwards J.L. (2008). Multiple human papillomavirus types replicate in 3A trophoblasts. Placenta. 29, 30-38.
44. Zenilman J.M. (2001). Chlamydia and cervical cancer: A real association? JAMA. 285, 81-83.